SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as the market reacts to the company's latest subscription price hikes, which analysts view as a strategic move to fund a massive content budget and solidify profitability. While some retail investors are voicing frustration over recurring cost increases, the community is heavily focused on the stock's relative strength and technical breakout potential, with many discussing its role as a hedge against broader market volatility.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is rallying as investors react to a strategic $14.2 billion deal to regain full ownership of its Ireland-based Fab 34, a move perceived as a major vote of confidence in the company's manufacturing and AI-driven growth trajectory. The community is actively debating the stock's future, with many interpreting the heavy capital reinvestment as a clear indicator that major new customer contracts are imminent.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is trending following the recent FDA approval of its rare disease drug, VYKAT XR, which has triggered intense market activity and discussions regarding the company's valuation, potential for a future buyout, and its ability to execute a successful commercial launch. Investors and traders are closely monitoring price action as the company transitions into a commercial-stage entity, with active debate surrounding its long-term growth prospects versus risks of dilution or volatility.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to heightened speculation surrounding a potential buyout, as market participants monitor recent biotech deal flow and comments from industry observers. While some investors focus on the company's robust obesity drug pipeline and late-stage clinical progress, others are actively debating the impact of competitive GLP-1 developments and broader macroeconomic volatility on its near-term valuation.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind this Solana-based meme coin as a satirical movement intended to mock established market structures, with community members actively comparing its long-term potential to industry giants. Discussions are currently dominated by enthusiasts promoting the token's cultural narrative and its goal of creating viral engagement within the broader crypto ecosystem.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending as the market reacts to the definitive agreement to acquire Soleno Therapeutics for $2.9 billion. Community sentiment is mixed, with active debate regarding whether the acquisition effectively addresses Neurocrine's need for pipeline growth or if the premium paid for the rare-disease asset signals a strategic overpay.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is currently trending as shareholders analyze the strategic implications of parent company Centurium Capitals acquisition of Blue Bottle Coffee. While the community remains divided over potential conflicts of interest versus synergistic growth, investors are closely monitoring for signs of a long-anticipated U.S. exchange relisting and are actively debating the stock's future valuation amid shifting institutional ownership.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altria Group is seeing significant investor interest driven by a combination of resilient pricing power in its core smokeable business and ongoing momentum in its smoke-free portfolio, particularly with the growth of its on! nicotine pouches. The community is actively debating the company's long-term pivot from traditional cigarettes toward smoke-free alternatives, with many highlighting the stock's role as a classic, high-yield defensive play in a volatile market.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently facing significant volatility following analyst downgrades and concerns over its debt load, coupled with investor anxiety regarding negative free cash flow and strategic pivots. While some market participants are monitoring the stock for potential short-squeeze dynamics, the community is actively debating the sustainability of its business model versus the possibility of a recovery in travel-driven revenue.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is seeing heightened community activity as investors weigh its exposure to volatile tech and crypto-linked assets against recent selling trends by ARK leadership. Discussion is primarily centered on skepticism regarding the fund's long-term performance and active debate over whether current market conditions offer a value entry or a trap for speculative growth investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating...

Oramed Pharmaceuticals (ORMP) to Release Earnings on Thursday

Oramed Pharmaceuticals (NASDAQ:ORMP) will be releasing earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-oramed-pharmaceuticals-inc-stock...

Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Declines By 16.2%

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 540,151...

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average - Here's Why

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Above 50-Day Moving Average - Here's What Happened...

<ul class="summary-bullets"><li>The reverse split would reduce the number of outstanding shares from about 18.3 million to around 1.5 million.</li><li>This marks the company’s second reverse stock split since March 2024, when it carried out a 1-for-7 consolidation.</li><li>Lifeward’s board also approved increasing the authorized share capital to 100 million shares.</li></ul>Shares of Lifeward (LFWD) slumped nearly 20% to their all-time low after the company announced it would implement a 1-for-12 reverse stock split effective Feb. 24, 2026.<a href="https://stocktwits.com/symbol/LFWD">LFWD</a> stock will begin trading on a post-split basis the same day under the existing ticker symbol. The move is aimed at boosting the share price to regain compliance with Nasdaq’s $1.00 minimum bid price requirement.<h2 class="st-heading-2">Outstanding Shares To Be Reduced To Around 1.5 Million</h2>The move follows shareholder approval in January, which authorized the board to determine whether to implement a reverse split of the company’s outstanding ordinary shares and, if so, to set the ratio within a range of 1-for-2 to 1-for-12, giving the board full discretion over the outcome.Under the reverse split, every 12 ordinary shares will automatically convert into one share, reducing outstanding shares from about 18.3 million to around 1.5 million. The board also approved increasing the authorized share capital to 100 million shares.This marks the company’s second reverse split in nearly two years. In March 2024, Lifeward completed a 1-for-7 reverse split of its ordinary shares, reducing the number of outstanding shares from around 60.1 million to about 8.6 million.<h2 class="st-heading-2">Partnership With Oramed For Protein Oral Delivery Technology</h2>In January, Lifeward partnered with Oramed Pharmaceuticals (ORMP) to integrate Oramed’s proprietary POD protein oral delivery technology into its platform.Under the terms of the deal, Oramed could acquire up to a 49.99% equity stake in Lifeward. The investment structure is expected to provide Lifeward with access to up to $47 million in capital through a combination of equity, convertible notes, milestone-based funding, and warrant coverage, supporting future growth initiatives.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Meanwhile, retail sentiment on Stocktwits remained in the ‘neutral’ zone over the past 24 hours.Year-to-date, the stock has declined around 25%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spai-stock-reverses-gains-safe-pro-us-government-ai-contract/cZRN7XMR4x0">This AI-Based Defense Company Secured A US Government Contract – So, Why Did The Stock Reverse Pre-Market Gains?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years

The company announced it would implement a 1-for-12 reverse stock split effective Feb. 24, 2026.

Equity

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 57.8% in January

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant growth in short interest in January. As of January 30th, there was short interest totaling 644,912 shares, a growth of...

Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving Average - Time to Sell?

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average - Should You Sell...

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Increase in Short Interest

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 424,089...

Oramed and Lifeward Announce Strategic Transaction

Oramed and Lifeward Announce Strategic Transaction Oramed and Lifeward Announce Strategic Transaction PR Newswire NEW YORK, Jan. 13, 2026 Transaction Will TransferOramed's Oral Drug Delivery Platform...

Oramed Reports Fiscal Third Quarter 2025 Financial Results

Oramed Reports Fiscal Third Quarter 2025 Financial Results Oramed Reports Fiscal Third Quarter 2025 Financial Results PR Newswire NEW YORK, Nov. 17, 2025 Strong Nine-Month Performance Driven by...

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Oramed Pharmaceuticals, Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

ORMP
Oramed Pharmaceuticals, Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ORMP News

ORMPOramed Pharmaceuticals, Inc